Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: A 2-year multicentre, comparative, prospective cohort study

Nephrology Dialysis Transplantation

Volumn 23, Issue 11, 2008, Pages 3711-3719

  Vychytil, Andreas ^a   Remón, César ^b   Michel, Catherine ^c   Williams, Paul ^d   Rodríguez Carmona, Ana ^e   Marrón, Belén ^f   Vonesh, Ed ^f   Van Der Heyden, Synke ^f   Filho, Jose C Divino ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^c BICHAT HOSPITAL   (France)

^d IPSWICH HOSPITAL   (United Kingdom)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f Baxter R and D Europe   (Belgium)

Author keywords

Biocompatibility; Glucose degradation products; Glucose polymer; Peptidoglycan; Sterile peritonitis

Indexed keywords

ANTIBIOTIC AGENT; EXTRANEAL;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; DIALYSIS SOLUTIONS; EUROPE; FEMALE; GLUCANS; GLUCOSE; HUMANS; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONITIS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 54149108997     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn322     Document Type: Article

References (51)

1. Plum J, Gentile S, Verger C et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39: 862-871
2. Wolfson M, Piraino B, Hamburger RJ et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40: 1055-1065
3. Davies SJ, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344
4. Finkelstein F, Healy H, Abu-Alfa A et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16: 546-554
5. Wilkie ME, Plant MJ, Edwards L et al. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997; 17: 84-87
6. Johnson DW, Arndt M, O'Shea A et al. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001; 2: 2
7. Bredie SJ, Bosch FH, Demacker PN et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001; 21: 275-281
8. Gradden CW, Ahmad R, Bell GM. Peritoneal dialysis: new developments and new problems. Diabet Med 2001; 18: 360-363
9. Sisca S, Maggiore U. Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients. Perit Dial Int 2002; 22: 727-729
10. Martikainen T, Teppo AM, Gronhagen-Riska C et al. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 2005; 23: 303-310
11. Adachi Y, Nakagawa Y, Nishio A. Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis. Perit Dial Int 2006; 26: 405-407
12. Goldsmith D, Jayawardene S, Sabharwal N et al. Allergic reactions to the polymeric glucose-based peritoneal dialysis fluid icodextrin in patients with renal failure. Lancet 2000; 355: 897
13. Divino Filho JC. Allergic reactions to icodextrin in patients with renal failure. Lancet 2000; 355: 1364-1365
14. Gokal R. Icodextrin-associated sterile peritonitis. Perit Dial Int 2002; 22: 445-448
15. de Fijter CW, Verbrugh HA, Oe LP et al. Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993; 21: 411-418
16. Thomas S, Schenk U, Fischer FP et al. In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. Am J Kidney Dis 1997; 29: 246-253
17. Posthuma N, ter Wee P, Donker AJ et al. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Perit Dial Int 1999; 19: 334-342
18. Pérez Fontán M, Rodríguez-Carmona A, Garcia-Naveiro R et al. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25: 274-284
19. Krishnan M, Thodis E, Ikonomopoulos D et al. Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Perit Dial Int 2002; 22: 573-581
20. Fourtounas C, Savidaki E, Dousdabanis P et al. Peritonitis during the first year after commencement of peritoneal dialysis has an impact on technique survival and patient morbidity. Adv Perit Dial 2006; 22: 50-54
21. Piraino B, Bailie GR, Bernardini J et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-131
22. Vonesh EF. Estimating rates of recurrent peritonitis for patients on CAPD. Perit Dial Bull 1985; 5: 59-65
23. Vonesh EF. Modelling peritonitis rates and associated risk factors for individuals on continuous ambulatory peritoneal dialysis. Stat Med 1990; 9: 263-271
24. Guo A, Wolfson M, Holt R. Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney Int 2002; 62(Suppl 81): S72-S79
25. Davies SJ, Brown EA, Frandsen NE et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609-1615
26. Bajo MA, Selgas R, Castro MA et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int 2000; 20: 742-747
27. Gokal R, Mistry CD, Peers EM. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter investigation of icodextrin in ambulatory dialysis. Perit Dial Int 1995; 15: 226-230
28. Dombros N, Dratwa M, Feriani M et al. European best practice guidelines for peritoneal dialysis. 3 peritoneal access. Nephrol Dial Transplant 2005; 20(Suppl 9): ix8-ix12
29. Freiman JP, Graham DJ, Reed TG et al. Chemical peritonitis following the intraperitoneal administration of vancomycin. Perit Dial Int 1992; 12: 57-60
30. Coronel F, Martin-Rabadan P, Romero J. Chemical peritonitis after intraperitoneal administration of amphotericin B in a fungal infection of the catheter subcutaneous tunnel. Perit Dial Int 1993; 13: 161-162
31. Thakur SS, Unikowsky B, Prichard S. Eosinophilic peritonitis in CAPD: treatment with prednisone and diphenhydramine. Perit Dial Int 1997; 17: 402-403
32. Mangram AJ, Archibald LK, Hupert M et al. Outbreak of sterile peritonitis among continuous cycling peritoneal dialysis patients. Kidney Int 1998; 54: 1367-1371
33. Tuncer M, Sarikaya M, Sezer T et al. Chemical peritonitis associated with high dialysate acetaldehyde concentrations. Nephrol Dial Transplant 2000; 15: 2037-2040
34. de Freitas DG, Gokal R. Sterile peritonitis in the peritoneal dialysis patient. Perit Dial Int 2005; 25: 146-151
35. Heering P, Brause M, Plum J et al. Peritoneal reaction to icodextrin in a female patient on CAPD. Perit Dial Int 2001; 21: 321-322
36. Montagnac R, Slingeneyer A, Schillinger F. Aseptic peritonitis: role of icodextrin. Nephrol Dial Transplant 2001; 16: 435-436
37. Reichel W, Schulze B, Dietze J et al. A case of sterile peritonitis associated with icodextrin solution. Perit Dial Int 2001; 21: 414-415
38. Williams PF, Foggensteiner L. Sterile/allergic peritonitis with icodextrin in CAPD patients. Perit Dial Int 2002; 22: 89-90
39. Goffin E, Scheiff JM. Transient sterile chemical peritonitis in a CAPD patient using icodextrin. Perit Dial Int 2002; 22: 90-91
40. Basile C, De Padova F, Montanaro A et al. The impact of relapsing sterile icodextrin-associated peritonitis on peritoneal dialysis outcome. J Nephrol 2003; 16: 384-386
41. Martis L, Patel M, Giertych J et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 2005; 365: 588-594
42. Nakagawa Y, Maeda H, Murai T. Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: comparison with a human whole blood culture test system and with the rabbit pyrogen test. Clin Diagn Lab Immunol 2002; 9: 588-597
43. Rozenberg R, Magen E, Weissgarten J et al. Icodextrin-induced sterile peritonitis: the Israeli experience. Perit Dial Int 2006; 26: 402-405
44. Enia G, Mandalari A, Ventura G et al. Sterile icodextrin- associated peritonitis may induce hypersensitivity and recurrent peritonitis on re-challenge. Nephrol Dial Transplant 2003; 18: 626
45. Goffin E. Aseptic peritonitis and icodextrin. Perit Dial Int 2006; 26: 314-316
46. Lee S, Schoen I. Eosinophilia of peritoneal fluid and peripheral blood associated with chronic peritoneal dialysis. Am J Clin Pathol 1967; 47: 638-640
47. Karanicolas S, Oreopoulos DG, Izatt S et al. Epidemic of aseptic peritonitis caused by endotoxin during chronic peritoneal dialysis. N Engl J Med 1977; 296: 1336-1337
48. Jager KJ, Stel VS, Wanner C et al. The valuable of observational studies to nephrology. Kidney Int 2007; 72: 671-675
49. Davies SJ, Phillips L, Naish PF et al. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092
50. Vychytil A, Lorenz M, Schneider B et al. New strategies to prevent staphylococcus aureus infections in peritoneal dialysis patients. J Am Soc Nephrol 1998; 9: 669-676
51. Chow KM, Szeto CC, Leung CB et al. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int 2005; 25: 374-379